LONDON, May 2, 2017 /PRNewswire/ --
Oryzon has been making steady progress with its epigenetics R&D pipeline.Following positive Phase I/IIa trial results in December 2016, ORY-1001, an LSD1 inhibitor, is now in Roche's hands and the company is focusing on its newer programmes: clinical-stage ORY-2001, a dual LSD1/MAOB inhibitor
(Logo: http://photos.prnewswire.com/prnh/20130417/608168 )
We have increased our valuation of Oryzon from €266m to €308m or €9.0/share (from €9.3/share) on the back of the recent financing round and higher success probability for AD. The main potential catalysts over the next 12-24 months are progress in the SCLC trial run by Roche, initiation of Phase II trials in neurodegenerative disorders with ORY-2001, new preclinical candidates entering the clinic and delivering first human data.
Click here to view the full report.
All reports published by Edison are available to download free of charge from its website
About Edison: Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
Edison is authorised and regulated by the Financial Conduct Authority.
Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.
Contact details: Learn more at http://www.edisongroup.com and connect with Edison on: LinkedIn http://www.linkedin.com/company/edison-investment-research Twitter http://www.twitter.com/Edison_Inv_Res YouTube http://www.youtube.com/edisonitv Google+ https://plus.google.com/105425025202328783163/posts
For more information please contact: Jonas Peciulis Edison Investment Research +44(0)20-3077-5728 Juan Pedro Serrate Edison Investment Research +44(0)20-3681-2534 [email protected]
SOURCE Edison Investment Research
Subscribe to our Free Newsletters!
Iridectomy is a procedure in which an opening is made in the iris of the eye.
Hand hygiene is a simple and affordable technique to prevent infections.
Erythropoietin is a hormone secreted by kidneys in response to low oxygen levels in tissues ...View All